Top Stock Losers
Explore the biggest stock losers today along with up-to-date performance data, including the latest price, share price changes, trading volume, and more. We cover the top stock losers and decliners every day with market data, news, and analysis from our Foolish experts.
Related Articles
Featured Article
Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript
Motley Fool Transcribing
|
Feb 26, 2025
SRPT earnings call for the period ending December 31, 2024.
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript
Motley Fool Transcribing
|
Nov 7, 2024
SRPT earnings call for the period ending September 30, 2024.
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
Motley Fool Transcribing
|
Aug 8, 2024
SRPT earnings call for the period ending June 30, 2024.
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
Alex Carchidi
|
Jul 6, 2024
One key issue remains unresolved, and it could be a significant one.
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
David Jagielski
|
Jul 4, 2024
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.
1 Soaring Growth Stock to Buy and Hold for 10 Years
Prosper Junior Bakiny
|
Jul 3, 2024
Let's look beyond the biotech's performance this year.
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
Motley Fool Transcribing
|
May 1, 2024
SRPT earnings call for the period ending March 31, 2024.
1 Top Growth Stock to Buy and Hold for 10 Years
Prosper Junior Bakiny
|
May 1, 2024
This company's lineup might look very different in a decade, but the end result will be the same for investors.
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Alex Carchidi
|
Mar 13, 2024
The threat is still emerging, but it could be significant.
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
Alex Carchidi
|
Mar 4, 2024
The upcoming regulatory decision on its latest drug could be big.
View More Articles